Filing Details

Accession Number:
0001209191-18-038646
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-19 17:49:05
Reporting Period:
2018-06-15
Accepted Time:
2018-06-19 17:49:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1368148 Athersys Inc / New ATHX Pharmaceutical Preparations (2834) 204864095
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1402609 Jr William Lehmann 3201 Carnegie Avenue
Cleveland OH 44115-2634
President And Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-06-15 7,889 $2.32 460,084 No 4 F Direct
Common Stock Acquisiton 2018-06-18 96,600 $0.00 556,684 No 4 A Direct
Common Stock Disposition 2018-06-19 14,000 $2.25 542,684 No 4 S Direct
Common Stock Disposition 2018-06-19 16,000 $2.24 526,684 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (right to purchase) Acquisiton 2018-06-18 230,004 $0.00 230,004 $2.31
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
230,004 2028-06-18 No 4 A Direct
Footnotes
  1. Shares withheld from the quarterly vesting of annual restricted stock unit awards related to the minimum tax withholding obligation.
  2. Award of annual restricted stock units, each of which represents a contingent right to receive one share of Athersys, Inc. common stock after vesting. The restricted stock units vest ratably on a quarterly basis over a three-year period.
  3. Shares sold pursuant to a predefined Rule 10b5-1 trading plan for tax and planning purposes.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.22 to $2.275, inclusive.
  5. Shares sold for tax and financial planning purposes.
  6. Securities beneficially owned are comprised of: (1) 223,504 shares of common stock owned and (2) unvested restricted stock units aggregating 303,180 related to annual awards, which vest quarterly over a three or four-year period from grant date.
  7. Award of an annual stock option. The option vests ratably on a quarterly basis over a three-year period.